Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2021-10-05 00:00:00 ET · period of report 2021-10-01 · accession 0001104659-21-123185 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-10-05 | 2021-10-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | S - Sale+OE | $4.89 | -27.5K | 17.2K | -62% | -$134.5K |
| D | 2021-10-05 | 2021-10-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | M - OptEx | $0.92 | +27.5K | 44.7K | +160% | +$25.3K |
| D | 2021-10-05 | 2021-10-01 | APRE | Korbel Gregory Alan | SVP, Chief Business Off | M - OptEx | $0.00 | -27.5K | 25.2K | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-01 | S | D | 27,500 | $4.89 | 17,167 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.06 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2021-10-01 | M | A | 27,500 | $0.92 | 44,667 | D | — | — | |
| 3 | Derivative | Stock Option (right to Buy) | 2021-10-01 | M | D | 27,500 | $0.00 | 25,245 | D | $0.92 · — to 2026-09-14 | 27,500 Common Stock | (F3) This option was granted on September 14, 2016 and is fully exercisable. |